Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 46Pituitary Neoplasms 19Neoplasms 14Thyroid Neoplasms 13Pheochromocytoma 13Thyroid Carcinoma, Anaplastic 12Thyroid Cancer, Papillary 12Neoplasm Metastasis 12Adrenocortical Carcinoma 11Paraganglioma 9Insulinoma 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Somatostatinoma 8Glucagonoma 8Colorectal Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Islet Cell 8Pancreatic Neoplasms 7Gastrinoma 7Carcinoma, Neuroendocrine 7Breast Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Adenoma, Islet Cell 6Small Cell Lung Carcinoma 5Multiple Endocrine Neoplasia Type 1 5Lung Neoplasms 5Gastro-enteropancreatic neuroendocrine tumor 5

Interventions

pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Nelson Syndrome × Endocrine × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡